{"entity":{"id":"nct06595186","kind":"trial","name":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","aka":[],"tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by JenKem Technology Co., Ltd., now recruiting.","summary":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) is a phase 2 interventional study registered as NCT06595186 by JenKem Technology Co., Ltd., with 25 participants planned, started 2022-10-31 and due to reach its primary completion in 2026-08-16. Interventions recorded: JK-1201I and Temozolomide (TMZ).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06595186","url":"https://clinicaltrials.gov/study/NCT06595186"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06595186","phase":"2","setting":"A Multicenter, Single Arm, Open-label, Dose-escalation Phase 2 Study of JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) After Surgery and Concomitant Radio-chemotherapy","sponsor":"JenKem Technology Co., Ltd.","enrolled":25,"outcomes":[]},"route":"/trials/nct06595186/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}